Our results defined significant genomic alterations in MYC pro-oncogene networking, as well as TGF-β signaling—including androgen/TGF-β signaling inhibitor PMEPA1 responding to curcumin treatment in both androgen-dependent and independent prostate cancer cells. The gene discussed is MYC; the disease is prostate carcinoma.